chrisvoncsefalvay/vaers-outcomes huggingface dataset:
extreme fatigue lasting 14 days - sleeping 14-16 hours a day - all symptoms lasted 14 days slight cough headache digestive upset nausea chills
Per call from patient she is still hospitalized. The evening after receiving her vaccines, she was feeling out of it and as she puts it catatonic. She was not aware of her surroundings for 36 hours and doesn't remember the in between. She says it feels similar to a stroke and is still having issues with speaking. She states she is a nurse and called to make sure this gets reported.
my arm is sore; feeling little sick; This case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 9th December 2021, the patient received the 1st dose of Shingles vaccine. In December 2021, less than a week after receiving Shingles vaccine, the patient experienced pain in arm and feeling unwell. On an unknown date, the outcome of the pain in arm and feeling unwell were unknown.   It was unknown if the reporter considered the pain in arm and feeling unwell to be related to Shingles vaccine.  Additional details were provided are as follows: The patient self-reported the case. The age at vaccination was not reported. The patient received a dose of Shingles vaccine day before vaccination and his/her arm was sore and feeling little sick. The follow-up could not be possible as no contact details were available.
Child received vaccine on 6/22/10.  Mom called on 6/24/10 to report that child had large (baseball) size lump on LA.  Area is red and swollen.  Child c/o pain at site.
Ten days after vaccination, started having audible wheezing/squeaking sounds when breathing.  Short of breath.  Doctor prescribed Abuterol inhaler.  No effect.  Doctor ordered chest X-Ray which did not show anything.  Referred to Pulmonologist, which I haven't seen yet.  7 months later still having breathing issues with audible wheezing.  Have never had any type of breathing issues or sounds like this in my life until I received the J&J vaccine.
This spontaneous report as received from an other unspecified source refers to a patient of unknown age and gender. On an unknown date the patient was vaccinated with a dose of improperly stored GARDASIL(lot# J003727, expiration date: 7-NOV-2015, dose and route not reported). This is one of several reports received from the same source (linked MARRS#'s: 1310USA014881, 1310USA014888, 1310USA014891, 1311USA000056, 1311USA000071, 1310USA015417, 1310USA014897, 1311USA000012, 1310USA014858, 1310USA014850, 1310USA014870, 1311USA000289, 1311USA000282, 1310USA014874, 1310USA014861, 1310USA014866, 1310USA014868, 1310USA015422, 1310USA015165, 1311USA000069, 1310USA015424, 1311USA000058, 1311USA000042, 1311USA000013, 1310USA015170, 1311USA000014, 1310USA015153, 1310USA015090, 1311USA000067, 1311USA000064, 1311USA000020, 1311USA000021, 1311USA000040, 1310USA015096, 1311USA000022, 1310USA015101, 1310USA014853, 1311USA000075, 1310USA014895, 1310USA015119, 1310USA015113, 1311USA000059, 1311USA004931, 1311USA000065, 1311USA000739. Additional information has been requested.
had an excursion that went up to 35 degrees F.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (had an excursion that went up to 35 degrees F.) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (had an excursion that went up to 35 degrees F.). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (had an excursion that went up to 35 degrees F.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported.  No treatment drug details was reported.
MUSCLE CRAMPS IN LEGS; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 27-MAR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On 27-MAR-2021, the subject experienced muscle cramps in legs. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from muscle cramps in legs. This report was non-serious.
stool was black; diarrhea/liquid poop; problems in her stomach; This is a spontaneous report received from a contactable reporter (Consumer) from medical information team. The reporter is the patient.  A 74-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) administration date 19Mar2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, Single, MANUFACTURER UNKNOWN (Lot # not provided)), for COVID-19 Immunisation. The following information was reported: DIARRHOEA (non-serious) with onset 24Mar2021, outcome "unknown", described as "diarrhea/liquid poop"; GASTRIC DISORDER (non-serious) with onset 24Mar2021, outcome "unknown", described as "problems in her stomach"; FAECES DISCOLOURED (non-serious), outcome "unknown", described as "stool was black". Additional Information: The patient received the second dose of the Covid 19 vaccine on March 19th. After a few days, on 24Mar2021, she started with diarrhea, it started in the morning. She had liquid poop and problems in her stomach. Yesterday her stool was watery and black. She forced herself to eat something yesterday, it may have hardened already. The patient asked if she should get tested to see if she has Covid.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient received the high dose FLUZONE and it has been one month and patient still has pain all up & down his arm.
Red splotch on arm at injection site, beginning about a week after the injection itself. Warm, some swelling and tenderness, occasionally itchy.
Severe headache, congestion, nausea, vomiting (bile), fatigue, chills
Swelling /inflammation of face on left cheek near nose; periorbital swelling around eye; This is a spontaneous report from a contactable consumer (patient). A 67-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, in Arm Left on 30Jan2021 17:00 as single dose for covid-19 immunisation (age at vaccination 67 years) at Clinic. Medical history included sulfa drugs allergy, asthma, GERD (gastrooesophageal reflux disease), glaucoma, high BP (Blood pressure), hypothyroidism, depression. Concomitant medications the patient received within 2 weeks of vaccination included acetaminophen; albuterol sulfate; brimonidine tartrate. The patient didn't received any other vaccines within 4 weeks prior to the COVID vaccine. On 02Feb2021 at 01:00 A.M, the patient experienced swelling /inflammation of face on left cheek near nose and another site as periorbital swelling around eye; both occurring on left side of face only. Patient spoke with triage nurse who indicated to use ice. Prior to vaccination, the patient wasn't diagnosed with COVID-19. Since the vaccination, the patient hasn't been tested for COVID-19. Case was reported as non-serious. Outcome of events was not recovered.  Information on the lot/batch number has been requested.
Patient received DTaP immunization in right upper arm. Later the evening, arm turned red and swollen and itching around injection site. Patient also ran low grade fever.
Shot was given at 9:28 am on a Friday. Patient's mother reported arm soreness (started 30 minutes after shot), extreme headache (started 45 minutes after shot), arm tingling and difficulty breathing (started the evening after the shot). Patient's mother stated difficulty breathing continued all Saturday and Sunday. The patient went to the urgent care on Monday. Urgent care told her she was fine and sent her home. Reportedly, patient is still having difficulty breathing at this point.
This case was reported by a consumer via call center representative and described the occurrence of nerve pain in a adult female patient who received SHINGRIX for prophylaxis. The patient's past medical history included shingles (had shingles in December 2017 and took antiviral medication) and rash (cleared in 2 weeks). Concurrent medical conditions included nerve pain (had nerve pain for a year but it was improving). In January 2019, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced nerve pain and condition aggravated. On an unknown date, the outcome of the nerve pain and condition aggravated were unknown. It was unknown if the reporter considered the nerve pain and condition aggravated to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient developed shingles and took antiviral medication. The rash cleared in 2 weeks, but she developed nerve pain. The pain was improving but after the patient got 1st dose of SHINGRIX, the nerve pain got bad again. The patient was in a hurry and did not provide any contact information. The reporter did not give consent to follow up.
Fatigue; Received a third dose of the vaccine; The nurse missed my deltoid; Slight tenderness at the injection site; A spontaneous report was received from a physician, who was a 37-year-old, female, patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the nurse missed my deltoid, slight tenderness at the injection site, received a third dose of the vaccine, and fatigue.       The patient's medical history was not provided. No relevant concomitant medications were reported.   On 26 Dec 2020, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. On 24 Jan 2021, the patient received their second of two planned doses. On 27 Jan 2021, the patient received a third dose of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection.   On 24 Jan 2021, the patient received her second dose of the vaccine and the nurse administering the vaccine missed her deltoid. The patient experienced slight tenderness at the injection site.  On 27 Jan 2021, the patient received a third dose of the vaccine.   On 29 Jan 2021, the patient reported she began experiencing fatigue on an undisclosed date. No treatment information provided.   The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the drug in response to the events is not applicable.  The outcome of the event, the nurse missed my deltoid, was considered resolved on 24 Jan 2021. The outcome of the event, received a third dose of the vaccine, was considered resolved on 27 Jan 2021. The outcome of the event, slight tenderness at the injection site, was considered resolved on 29 Jan 2021. The outcome of the event, fatigue, was unknown.; Reporter's Comments: This case concerns a 37 year old female subject  who experienced non-serious events of nurse missed my deltoid, slight tenderness at the injection site, received a third dose of the vaccine, and fatigue after a second and third dose of mRNA-1273.  A third dose was given as second dose was not injected into deltoid muscle. All events had resolved at the time of this report. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
I developed burning, pain, and a rash on my left lower back and left gluteus maximus. It was diagnosed as Shingles on 3/26/2021 and I was given an antiviral drug to clear it up.  The rash has stopped progressing , but it is still visible. I also continue to have radiating pain and tingling, from my lower back to my big toe, along my sciatic nerve.
Arm that received the injection of PNEUMOVAX 23 (right arm) was sore and she rash on bicep and tricep area. Rash sites were warm to touch and felt harder than surrounding tissue.
Patient was given two doses of Polio vaccine booster.  She was there for her 4th dose, but a medical assistant there gave her a third shot (according to the doctor it was a second polio booster), instead of the two boosters she was scheduled for.
Tachycardia up to 115, jolting heart beat for numerous hours, low grade fever, slight chills
Patient received a Pfizer Bivalent vaccination on 09/24/2022 and then made another appointment and received another Bivalent on 12/20/2022. We spoke to patient and she had no adverse effects. When asked patient said she was getting the newest vaccination in December. When asked what she thought she got in September she was unclear. We collected her vaccination cards before the shot but failed to look on the back of one of the cards which had the September date on it
passed out three hours later, came to fine.  was light headed and cold like for a day.
Severe headache; Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 15-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0177) via an unspecified route of administration in the left arm on 19May2021 at 15:00 (at the age of 15-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any known allergies to food, medications, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20May2021 at 09:00, the patient experienced severe headache and extreme fatigue. The events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Therapeutic measures were not taken as a result of adverse events. The clinical outcome of the events severe headache and extreme fatigue was resolved on an unknown date in May2021.  No follow-up attempts are needed. No further information is expected.
pt recv vax & mom reported pt devel h/a, swollen tonsils, tender abd, light brown stools, sensation of sandpaper inside eyelids & lethargy w/interfered w/ability to walk;pt seen @ tertiary care ctr dx of serum sickness made;
Left thigh became warm and erythematous, with some swelling and mild induration at site of vaccine administration.
After getting the vaccine a couple of months later I had a break through after having COVID-19. Some side effects I had after getting the vaccine was a sore arm and experienced fatigue.
Splitting headache in the afternoon followed by  100.8 fever, chills, and body aches starting about 2 AM.
This is a spontaneous case, initially received from other non-health professional (consumer) on 24-Oct-2018, concerns a 35-year-old, adult, female patient. The patient's current conditions included: IgA deficiency, gluten intolerance and was allergic to peroxide based products and ROCEPHIN (reported as medical history). The concomitant medication included: Retinol (reported as retinol A) for an unknown indication. On an unspecified date in Oct-2018, the patient was administered expired FLUCELVAX QIVc (dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number and expiry date: not reported). On an unspecified date in Oct-2018 (same day of vaccination), 10 minutes after vaccination, the patient experienced heat going up her neck and developed face tingling. The events lasted only for few minutes (reported as less than 10 minutes). The patient didn't receive any treatment associated with the events. At the time of the report, the patient had recovered from the events. The reporter assessed the case as non-serious.
Normal reactions were elevated temp 100.6, headache and body aches.   Abnormal reaction, swollen lymph node under right arm.
This case was reported in a literature and described the occurrence of Bell's Palsy in a subject who received Meningococcal ACWY-CRM vaccine. Concurrent medical conditions included eczema. On an unknown date, 1 day after receiving Meningococcal ACWY-CRM vaccine, the subject developed Bell's Palsy. Serious criteria included GSK medically significant. The outcome of Bell's Palsy was recovered/resolved. It was unknown if the investigator considered the Bell's Palsy to be related to Meningococcal ACWY-CRM vaccine. Additional information was provided. This case was reported in a literature article and described the occurrence of Bell's Palsy in a patient aged 11-and-21 year of unspecified gender who was vaccinated with MENVEO (GlaxoSmithKline). The patient was a part of a self-controlled post licensure safety that evaluated the safety profile of quadrivalent meningococcal conjugate vaccine in a large cohort age 11 to 21 years. The patient belonged to the risk window. [In this study, the risk window was 1-84 days: time period in which it was hypothesized that the risk of events might be affected by vaccination-following index vaccination (first dose of vaccination)]. The patient's concurrent condition was eczema. The patient had not received any concomitant vaccine. No information on patient's family history or concomitant medication was provided. On an unspecified date between 30 September 2011 and 30 June 2013, the patient received MENVEO (administration route and site unknown; dosages unknown; batch number not provided) at a participating medical centre. On an unspecified date, between 1 and 84 days post index vaccination, the patient developed Bell's Palsy. In this study, cases in the risk window occurred primarily between 5 and 10 weeks after vaccination. Treatment was unknown. The event resolved completely. The authors stated that "there is no clear biological plausibility for a causal relationship between vaccination and Bell's Palsy." The authors concluded that "This observational study was not intended to provide conclusive evidence of causality. Rather, it detected potential temporal associations between MenACWY-CRM vaccination and adverse events. With nearly 50 000 individuals vaccinated with MenACWY-CRM included in this study, we observed a temporal association between occurrence of Bell's Palsy and receipt of MenACWY-CRM concomitantly with other vaccines. The association needs further investigation because it could be due to chance, concomitant vaccination, or underlying medical history predisposing to Bell's Palsy". This is 1 of the 8 valid cases reported in the same literature article.
having a metallic tasts in her mouth; This is a spontaneous report received from a contactable consumer (patient). A 66-year-old female patient received a second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation solution for injection) via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. The patient's medical history stated she lost her sense of smell and had covid back in November. Patient historical vaccine included BNT162B2 (first dose) for COVID-19 immunization. Patient concomitant medications were not reported. Caller stated that she got her first vaccine dose and it went well. Then she went for her second dose and several days later she began having a metallic tasts in her mouth on an unspecified date. She didn't see this listed as a common side effect and reports that when she had Covid back in November "she had lost her sense of smell but she had no other symptoms". Patient reported that she still hasn't gotten her taste back yet and reports that her smell is coming back. The outcome of the event was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Vaccine administered after after 4 temperature excursions; Vaccine administered after after 4 temperature excursions; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 023H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after after 4 temperature excursions) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after after 4 temperature excursions).    No concomitant medications were reported.   It was unknown if patient receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.  It was reported that vaccine was moved from freezer to refrigerator on 12/2/22 of the ten vials in question 43 injections were given and 7 doses were wasted. Vaccine administered after after 4 temperature excursions.  No treatment medication was provided.  This case contains information for the 24th of 43 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-689222 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-689222:Master case
This spontaneous report was received from a Registered Nurse (R.N) concerning multiple unspecified patients of unknown age and gender. The patients' pertinent medical history and concurrent conditions were not reported. On an unknown date, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB (Lot # L044694; expiration date 04-FEB-2018), (Lot # M000442; expiration date 31-MAR-2018), (Lot # M003658; expiration date 02-JUN-2018), (Lot # M029233; expiration date 09-AUG-2018), (Lot # M045653; expiration date 03-JUL-2019) for prophylaxis (dose and route not reported). The temperature was 9°C to 25°C for 210 hours and there was no previous temperature excursion. The call was made because of a data logger. Adverse effects reported and there was no PQC involved. This is one of several cases from the same source. Sender's Comments: US-009507513-1708USA003628: US-009507513-1708USA003629: US-009507513-1708USA003635: US-009507513-1708USA003631: US-009507513-1708USA011937: US-009507513-1708USA003633: US-009507513-1708USA003634: US-009507513-1708USA003627: US-009507513-1708USA003630.